i am having troulbe copying page 18 in tabel format. but please go there and look PONA is such a superior drug and just needs time to play out. Table 02: Effect of Ponatinib, Imatinib, Nilotinib, and Dasatinib on Viability of Ba/F3 Cells Dependent on Native or 14 Mutant Variants of BCR-ABL Ba/F3 Cell Viability Assay IC50 (nM) BCR-ABL Ponatinib1 Imatinib2 Nilotinib2 Dasatinib2 Native 0.5 260 13 0.8 M244V 2.2 2000 38 1.3 G250E 4.1 1350 48 1.8 Q252H 2.2 1325 70 3.4 Y253F 2.8 3475 125 1.4 Y253H 6.2 >6400 450 1.3 E255K 14 5200 200 5.6 E255V 36 >6400 430 11 T315A 1.6 971 61 125 T315I 11 >6400 >2000 >200 F317L 1.1 1050 50 7.4 F317V 10 350 nd 53 M351T 1.5 880 15 1.1 F359V 10 1825 175 2.2 H396P 1.1 850 41 0.6 Parental 1713 >6400 >2000 >200 1: Report OHSU-001 2: O'Hare T. et al (2005) Cancer Res. 65: 4500-4505. O'Hare T. et al (2007) Blood. 110: 2242-2249. nd=not determined